DYAI

Dyadic International, Inc. is a biotechnology company focused on developing its proprietary C1 gene expression platform for use in biologic drug manufacturing and vaccine development. The C1 platform uses a fungal microorganism to produce proteins and enzymes more efficiently and cost-effectively than traditional mammalian cell culture systems. Dyadic's technology has potential applications in producing biosimilars, vaccines, antibodies, and enzymes for industrial and pharmaceutical use. The company has research and licensing collaborations with pharmaceutical and biotechnology companies to develop and commercialize products using the C1 platform. Dyadic aims to make biologic drugs more affordable and accessible by reducing manufacturing costs.